GLS and gastrointestinal stromal tumor: There have been two clinical trials adjusted for SDH-deficient GIST among other neoplasms, NCT02071862 involving glutaminase inhibitor CB-839 and NCT03165721 with guadecitabine (SGI-110), though both were cessated and no results have been published.